The I-SPY clinical trials are forging a path toward a novel clinical research paradigm, designed to minimize inefficiencies, prioritize patient well-being, and establish a practical framework for precision-based drug development. The central question now is whether this approach will be adopted beyond breast cancer.
The latest iteration, I-SPY 2.2, expands upon the earlier adaptive platform design for neoadjuvant breast cancer therapies by incorporating precision medicine into the protocol. It further advances the underlying theme of patient-centricity through frequent monitoring, early trial exit points, and a treatment block design that minimizes toxicity and exposure to ineffective therapies.
